Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Cell Therapeutics Inc. Stories

2013-11-07 16:30:46

- Pacritinib Phase 2 Analysis of Myelofibrosis Patients with Thrombocytopenia (Low Platelets) Accepted for Oral Presentation - SEATTLE, Nov. 7, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the upcoming presentations of data highlighting pacritinib, a novel, oral JAK2/FLT3 inhibitor, and tosedostat, an aminopeptidase inhibitor, at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 7-10, 2013 in New...

2013-10-30 16:25:43

- Conference call scheduled today at 4:30 p.m. Eastern time - SEATTLE, Oct. 30, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported financial results for the third quarter and nine months ended September 30, 2013. "We recently achieved an important clinical milestone in our pacritinib development program, having reached agreement with the FDA on a Special Protocol Assessment (SPA) for the planned pivotal Phase 3 PERSIST-2 clinical trial of pacritinib for...

2013-10-23 04:23:15

- Conference call and webcast at 4:30 p.m. Eastern Time - SEATTLE, Oct. 23, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that it will report its third quarter financial results on Wednesday, October 30, 2013, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update at 4:30 p.m. EDT (1:30...

2013-10-21 04:20:56

-- Findings Suggest New Class of Anti-Cancer Agents with Novel Mechanism for Tumor Cell Killing -- SEATTLE, Oct. 21, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the presentation of findings from a preclinical study of PIXUVRI(®) (pixantrone) that suggest its mechanism of inducing tumor cell death is novel and distinct from that of anthracyclines such as doxorubicin. PIXUVRI is a first-in-class aza-anthracenedione with unique structural...

2013-10-15 04:21:01

SEATTLE, Oct. 15, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that the National Institute for Health and Care Excellence (NICE), a non-departmental public body of the Department of Health in the United Kingdom (UK), issued second draft guidance on PIXUVRI(®) (pixantrone) as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (aggressive B-cell NHL). NICE's...

2013-10-14 04:21:29

SEATTLE, Oct. 14, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) today announced the addition of three leaders in the research and development of new treatments for blood-related cancers to CTI's recently formed Scientific Advisory Board (SAB): Alan List, M.D., President and CEO of Moffitt Cancer Center; Ross Levine, M.D., Associate Attending Physician at Memorial Sloan-Kettering Cancer Center; and Brian Druker, M.D., Director of the Knight Cancer...

2013-10-10 08:26:04

NEW YORK, October 10, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), Cell Therapeutics, Inc. (NASDAQ: CTIC), PDL BioPharma, Inc. (NASDAQ: PDLI), Halozyme Therapeutics, Inc. (NASDAQ: HALO), and Acorda Therapeutics, Inc. (NASDAQ: ACOR). Today's readers may access these reports free of charge - including...

2013-10-07 04:20:50

- PERSIST-2 trial expected to initiate in fourth quarter of 2013 - SEATTLE, Oct. 7, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that the company reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the planned pivotal Phase 3 clinical trial, known as the PERSIST-2 trial, evaluating pacritinib compared to best available therapy, including approved JAK2 inhibitors such as ruxolitinib,...

2013-09-19 04:21:05

SEATTLE, Sept. 19, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) today announced the closing of its previously announced sale of 15,000 shares of its Series 18 Preferred Stock directly to Quogue Capital LLC and an affiliate of Perceptive Advisors LLC in a registered direct offering conducted without an underwriter or placement agent for gross proceeds of approximately $15 million (the "Offering"). On September 18, 2013, all of the shares of Series 18...

2013-09-13 04:21:41

SEATTLE, Sept. 13, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) today announced that it has agreed to sell 15,000 shares of its Series 18 Preferred Stock directly to Quogue Capital LLC and an affiliate of Perceptive Advisors LLC in a registered direct offering conducted without an underwriter or placement agent for gross proceeds of approximately $15 million (the "Offering"). The net proceeds from the Offering, after deducting estimated offering...